Alembic reports 11% growth in revenue for Q4 FY22 from INR 1280 Cr. in FY21 to INR 1416 Cr.

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st March 2022.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said “India Branded Business continues to deliver strong market beating growth in Q4. India Business witnessed market outperforming growth across most of the products and therapy areas.”

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The US Business grew 17% in the quarter. We continue to remain focused on the US Business hence we acquired the balance 40% stake in Aleor Dermaceuticals, making it a wholly owned subsidiary of the Company”.

Net Profit After Tax for the quarter is Rs. 35 Cr. post charging off non-recurring expense of Rs. 188 Cr.

Operational Highlights

International Generics
23 ANDA filed in FY22. Cumulative ANDA filings at 230.
23 ANDA approvals received in FY22 Cumulative ANDA approvals 160
US Generics at Rs 557 Cr. in the quarter and at Rs 1666 Cr. for FY22.
Ex-US International Formulations at Rs. 188 Crores in the quarter and at Rs 775 Cr. for FY22.

India Branded Business
India Branded Business at Rs 449 Cr. in the quarter and at Rs 1926 Cr. (growth of 25% and 29% respectively) in the FY22.
Acute & most specialty segments grew faster than IPM.

API
API business at Rs 222 Cr. in the quarter and at Rs 939 Cr. for FY22.
3 DMFs were filed in the quarter.

About Post Author

THE INDIA WIRE NETWORK

maulikk.buch@gmail.com

http://theindiawire.com

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %